JIP
VRTX icon

Jaffetilchin Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-401
Closed -$186K – 1291
2024
Q3 		$186K Buy
+401
New +$193K 0.01% 365
2019
Q3 		– Sell
-1,712
Closed -$314K – 269
2019
Q2 		$314K Buy
+1,712
New +$299K 0.07% 186
2018
Q2 		– Sell
-1,417
Closed -$231K – 367
2018
Q1 		$231K Buy
+1,417
New +$231K 0.05% 287

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Jaffetilchin Investment Partners's VRTX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 401 shares — an estimated $186K sold.

Jaffetilchin Investment Partners first reported a position in VRTX in Q1 2018 and held it in 3 quarters. The position peaked at $314K in Q2 2019. 1,558 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 401 Vertex Pharmaceuticals shares in Q4 2024, an estimated $186K.
  • Jaffetilchin Investment Partners first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Jaffetilchin Investment Partners's Vertex Pharmaceuticals position peaked at $314K in Q2 2019.
  • 1,558 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.